WFDC2 and endometrial cancer: Our study suggests that HE4 and, to a lesser extent CA125, show promise as non-invasive endometrial cancer diagnostic biomarkers, discriminating endometrial cancer cases from healthy and symptomatic controls with a combined AUC of 0.77, and a sensitivity of 80.6% at published thresholds, using the strategy where either marker was positive.